|
1
|
Martinez-Outschoorn UE, Sotgia F and
Lisanti MP: Caveolae and signalling in cancer. Nat Rev Cancer.
15:225–237. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Huang B, Song BL and Xu C: Cholesterol
metabolism in cancer: Mechanisms and therapeutic opportunities. Nat
Metabol. 2:132–141. 2020. View Article : Google Scholar
|
|
3
|
Chimento A, Casaburi I, Avena P, Trotta F,
De Luca A, Rago V, Pezzi V and Sirianni R: Cholesterol and its
metabolites in tumor growth: Therapeutic potential of statins in
cancer treatment. Front Endocrinol (Lausanne). 9:8072019.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chang TY, Chang CC, Ohgami N and Yamauchi
Y: Cholesterol sensing, trafficking, and esterification. Annu Rev
Cell Dev Biol. 22:129–157. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kuzu OF, Noory MA and Robertson GP: The
role of cholesterol in Cancer. Cancer Res. 76:2063–2070. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Stäubert C, Krakowsky R, Bhuiyan H, Witek
B, Lindahl A, Broom O and Nordström A: Increased lanosterol
turnover: A metabolic burden for daunorubicin-resistant leukemia
cells. Med Oncol. 33:62016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Repa JJ and Mangelsdorf DJ: The liver X
receptor gene team: Potential new players in atherosclerosis. Nat
Med. 8:1243–1248. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ding Z, Gu Y, Huang D, Zhou H, Zhu T, Luo
X, Zhang S, Zhang S and Qian Y: Cholesterol biosynthesis inhibitor
RO 48-8071 inhibits pancreatic ductal adenocarcinoma cell viability
by deactivating the JNK and ERK/MAPK signaling pathway. Mol Med
Rep. 24:8282021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liang Y, Mafuvadze B, Aebi JD and Hyder
SM: Cholesterol biosynthesis inhibitor RO 48-8071 suppresses growth
of hormone-dependent and castration-resistant prostate cancer
cells. Onco Targets Ther. 9:3223–3232. 2016.PubMed/NCBI
|
|
10
|
Zhou XN, Li GM, Xu YC, Zhao TJ and Wu JX:
Knockdown of decoy Receptor 3 impairs growth and invasiveness of
hepatocellular carcinoma cell line of hepG2. Chin Med J (Engl).
129:2623–2629. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cruz PM, Mo H, McConathy WJ, Sabnis N and
Lacko AG: The role of cholesterol metabolism and cholesterol
transport in carcinogenesis: A review of scientific findings,
relevant to future cancer therapeutics. Front Pharmacol. 4:1192013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Phillips RE, Yang Y, Smith RC, Thompson
BM, Yamasaki T, Soto-Feliciano YM, Funato K, Liang Y,
Garcia-Bermudez J, Wang X, et al: Target identification reveals
lanosterolsynthase as a vulnerability in glioma. Proc Natl Acad Sci
USA. 116:7957–7962. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rowe AH, Argmann CA, Edwards JY, Sawyez
CG, Morand OH, Hegele RA and Huff MW: Enhanced synthesis of the
oxysterol 24(S), 25-epoxycholesterol in macrophages by inhibitors
of 2,3-oxidosqualene: Lanosterol cyclase: A novel mechanism for the
attenuation of foam cell formation. Circ Res. 93:717–725. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
de Freitas FA, Levy D, Zarrouk A, Lizard G
and Bydlowski SP: Impact of oxysterols on cell death,
proliferation, and differentiation induction: Current status.
Cells. 10:23012021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Eisele B, Budzinsky R, Muller P, Maier R
and Mark M: Effects of a novel 2,3-oxidosqualene cyclase inhibitor
on cholesterol biosynthesis and lipid metabolism in vivo. J Lipid
Res. 38:564–575. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Staedler D, Chapuis-Bernasconi C, Dehmlow
H, Fischer H, Juillerat-Jeanneret L and Aebi JD: Cytotoxic effects
of combination of oxidosqualene cyclase inhibitors with
atorvastatin in human cancer cells. J Med Chem. 55:4990–5002. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Maione F, Oliaro-Bosso S, Meda C, Di
Nicolantonio F, Bussolino F, Balliano G, Viola F and Giraudo E: The
cholesterol biosynthesis enzyme oxidosqualene cyclase is a new
target to impair tumour angiogenesis and metastasis dissemination.
Sci Rep. 5:90542015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mafuvadze B, Liang Y and Hyder SM:
Cholesterol synthesis inhibitor RO 48-8071 suppresses
transcriptional activity of human estrogen and androgen receptor.
Oncol Rep. 32:1727–1733. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liang Y, Besch-Williford C, Aebi JD,
Mafuvadze B, Cook MT, Zou X and Hyder SM: Cholesterol biosynthesis
inhibitors as potent novel anti-cancer agents: Suppression of
hormone-dependent breast cancer by the oxidosqualene cyclase
inhibitor RO 48-8071. Breast Cancer Res Treat. 146:51–62. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sherr CJ: G1 phase progression: Cycling on
cue. Cell. 79:551–555. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Massagué J: G1 cell-cycle control and
cancer. Nature. 432:298–306. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Blagosklonny MV and Pardee AB: The
restriction point of the cell cycle. Cell Cycle. 1:103–110. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Garcia-Ruiz C, Conde de la Rosa L, Ribas V
and Fernandez-Checa JC: Mitochondrial cholesterol and cancer. Semin
Cancer Biol. 73:76–85. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Siddiqui WA, Ahad A and Ahsan H: The
mystery of BCL2 family: Bcl-2 proteins and apoptosis: An update.
Arch Toxicol. 89:289–317. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Desagher S and Martinou JC: Mitochondria
as the central control point of apoptosis. Trends Cell Biol.
10:369–377. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kirsch DG, Doseff A, Chau BN, Lim DS, de
Souza-Pinto NC, Hansford R, Kastan MB, Lazebnik YA and Hardwick JM:
Caspase-3-dependent cleavage of Bcl-2 promotes release of
cytochrome C. J Biol Chem. 274:21155–21161. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wan FY and Lenardo MJ: The nuclear
signaling of NF-kappaB: Current knowledge, new insights, and future
perspectives. Cell Res. 20:24–33. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Samanta S, Yang S, Debnath B, Xue D, Kuang
Y, Ramkumar K, Lee AS, Ljungman M and Neamati N: The
Hydroxyquinoline analogue YUM70 Inhibits GRP78 to induce ER
stress-mediated apoptosis in pancreatic cancer. Cancer Res.
81:1883–1895. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang Y, Zhou L, Safran H, Borsuk R, Lulla
R, Tapinos N, Seyhan AA and El-Deiry WS: EZH2i EPZ-6438 and HDACi
vorinostat synergize with ONC201/TIC10 to activate integrated
stress response, DR5, reduce H3K27 methylation, ClpX and promote
apoptosis of multiple tumor types including DIPG. Neoplasia.
23:792–810. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sumei Z, Shaolong C, Xiang W, Yinliang Q,
Qing Z and Yuan W: Endocan reduces the malign grade of gastric
cancer cells by regulating associated proteins expression. Tumour
Biol. 37:14915–14921. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xu Z, Zhang S, Zhou Q, Wang Y and Xia R:
Endocan, a potential prognostic and diagnostic biomarker of acute
leukemia. Mol Cell Biochem. 395:117–123. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Youssef AA, Issa HA, Omar MZ, Behiry EG,
Elfallah AA, Hasaneen A, Darwish M and Ibrahim DB: Serum human
endothelial cell-specific molecule-1 (endocan) and vascular
endothelial growth factor in cirrhotic HCV patients with liver
cancer as predictors of mortality. Clin Exp Gastroenterol.
11:431–438. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Béchard D, Gentina T, Delehedde M,
Scherpereel A, Lyon M, Aumercier M, Vazeux R, Richet C, Degand P,
Jude B, et al: Endocan is a novel chondroitin sulfate/dermatan
sulfate proteoglycan that promotes hepatocyte growth factor/scatter
factor mitogenic activity. J Biol Chem. 276:48341–48349. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Depontieu F, Grigoriu BD, Scherpereel A,
Adam E, Delehedde M, Gosset P and Lassalle P: Loss of Endocan
tumorigenic properties after alternative splicing of exon 2. BMC
Cancer. 8:142008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yang YC, Pan KF, Lee WJ, Chang JH, Tan P,
Gu CC, Chang WM, Yang SF, Hsiao M, Hua KT and Chien MH: Circulating
proteoglycan endocan mediates EGFR-driven progression of non-small
cell lung cancer. Cancer Res. 80:3292–3304. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Shin JW, Huggenberger R and Detmar M:
Transcriptional profiling of VEGF-A and VEGF-C target genes in
lymphatic endothelium reveals endothelial-specific molecule-1 as a
novel mediator of lymphangiogenesis. Blood. 112:2318–2326. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ricoult SJ, Yecies JL, Ben-Sahra I and
Manning BD: Oncogenic PI3K and K-Ras stimulate de novo lipid
synthesis through mTORC1 and SREBP. Oncogene. 35:1250–1260. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Parra-Mercado GK, Fuentes-Gonzalez AM,
Hernandez-Aranda J, Diaz-Coranguez M, Dautzenberg FM, Catt KJ,
Hauger RL and Olivares-Reyes JA: CRF1 receptor signaling via the
ERK1/2-MAP and Akt kinase cascades: Roles of Src, EGF receptor, and
PI3-kinase mechanisms. Front Endocrinol (Lausanne). 10:8692019.
View Article : Google Scholar : PubMed/NCBI
|
